177 related articles for article (PubMed ID: 30115088)
1. Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies.
Zhang Y; He Y; Li L; Liang S; Yan M; Ren D; Yang Z; Zhao W; Miao L; Zhang H; Liu Y
Diagn Pathol; 2018 Aug; 13(1):55. PubMed ID: 30115088
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
4. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
[TBL] [Abstract][Full Text] [Related]
5. Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.
Liu HB; Chaturvedi PK; Battogtokh G; Bang HJ; Kim IW; Kim YW; Park KS; Ahn WS
Mol Biotechnol; 2013 Jun; 54(2):361-70. PubMed ID: 22669586
[TBL] [Abstract][Full Text] [Related]
6. Development of HPV58 type-specific antibodies and detection kit.
Liu Y; Zhang Y; Zhang G; Yang Z; Wang Y; Wu S; Chen D; Zhang H; Liu Y
Prep Biochem Biotechnol; 2023; 53(2):223-229. PubMed ID: 35465823
[TBL] [Abstract][Full Text] [Related]
7. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
8. Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein.
Wang Y; Shang Q; Xu W; Li D; Gu H; Wei L
Diagn Pathol; 2014 May; 9():101. PubMed ID: 24884993
[TBL] [Abstract][Full Text] [Related]
9. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
11. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
12. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
15. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
16. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
[TBL] [Abstract][Full Text] [Related]
17. Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies.
Li N; Zhang G; Chen Y; Zhou J; Hui C; Li S; Liu H; Liu Y; Qi Y; Wang A
Int J Biol Macromol; 2021 Mar; 174():587-595. PubMed ID: 33493568
[TBL] [Abstract][Full Text] [Related]
18. Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.
Huang B; Zhu L; Wei H; Shi H; Zhang D; Yuan H; Luan L; Zheng N; Xu S; Nawaz W; Hong Y; Wu X; Wu Z
Front Immunol; 2021; 12():678318. PubMed ID: 34248960
[TBL] [Abstract][Full Text] [Related]
19. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
